A new concept for bisphosphonate therapy

A rationale for the development of monthly oral dosing of ibandronate

Jean Yves Reginster, Dieter Felsenberg, Cyrus Cooper, Jacob A. Stakkestad, Paul D. Miller, David L. Kendler, Silvano Adami, Michael R. McClung, Michael A. Bolognese, Roberto Civitelli, Etienne Dumont, Bernard Bonvoisin, Robert R. Recker, Pierre D. Delmas

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

Oral daily and weekly bisphosphonates represent the current mainstay of treatment for postmenopausal osteoporosis (PMO). However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long term. This has prompted the development of convenient oral bisphosphonate regimens that feature simple, less frequent dosing schedules. Such regimens require high potency agents, which can be given at low effective doses and that also have good tolerability. Ibandronate is a potent, nitrogen-containing bisphosphonate with proven efficacy when given intermittently to estrogen-depleted beagle dogs, rats and cynomolgus monkeys. Clinically, a pivotal prospective study has established that oral ibandronate has significant vertebral fracture efficacy in PMO, whether given daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months; extended between-dose interval >2 months). Both oral regimens were well tolerated, which is noteworthy as patients with a history of gastrointestinal (GI) disturbance were not specifically excluded. As a result of these findings, a large, multinational, randomized, double-blind study (Monthly Oral iBandronate In LadiEs: MOBILE) is currently exploring the non-inferiority of once-monthly oral ibandronate (100 or 150 mg) to the oral daily ibandronate (2.5 mg) regimen with proven anti-fracture efficacy, in terms of lumbar spine bone mineral density (BMD) change. As with the trials investigating the weekly administration of other bisphosphonates, vertebral fracture efficacy will be inferred if the study demonstrates the non-inferiority of once-monthly ibandronate to the proven oral daily regimen in terms of spinal BMD change. The availability of this once-monthly ibandronate regimen is expected to offer benefits in terms of convenience (by having to follow dosing recommendations once a month vs. once daily or weekly) and potentially tolerability (by reducing the potential for upper GI irritation that can result from frequent, repeated exposure). Greater convenience and tolerability may enhance the therapy adherence and, hence, improve long-term therapeutic outcomes in PMO.

Original languageEnglish
Pages (from-to)159-166
Number of pages8
JournalOsteoporosis International
Volume17
Issue number2
DOIs
StatePublished - Feb 2006

Fingerprint

Diphosphonates
Postmenopausal Osteoporosis
Bone Density
Therapeutics
Macaca fascicularis
ibandronic acid
Double-Blind Method
Appointments and Schedules
Estrogens
Spine
Nitrogen
Prospective Studies
Dogs

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Reginster, J. Y., Felsenberg, D., Cooper, C., Stakkestad, J. A., Miller, P. D., Kendler, D. L., ... Delmas, P. D. (2006). A new concept for bisphosphonate therapy: A rationale for the development of monthly oral dosing of ibandronate. Osteoporosis International, 17(2), 159-166. https://doi.org/10.1007/s00198-005-1957-6

A new concept for bisphosphonate therapy : A rationale for the development of monthly oral dosing of ibandronate. / Reginster, Jean Yves; Felsenberg, Dieter; Cooper, Cyrus; Stakkestad, Jacob A.; Miller, Paul D.; Kendler, David L.; Adami, Silvano; McClung, Michael R.; Bolognese, Michael A.; Civitelli, Roberto; Dumont, Etienne; Bonvoisin, Bernard; Recker, Robert R.; Delmas, Pierre D.

In: Osteoporosis International, Vol. 17, No. 2, 02.2006, p. 159-166.

Research output: Contribution to journalReview article

Reginster, JY, Felsenberg, D, Cooper, C, Stakkestad, JA, Miller, PD, Kendler, DL, Adami, S, McClung, MR, Bolognese, MA, Civitelli, R, Dumont, E, Bonvoisin, B, Recker, RR & Delmas, PD 2006, 'A new concept for bisphosphonate therapy: A rationale for the development of monthly oral dosing of ibandronate', Osteoporosis International, vol. 17, no. 2, pp. 159-166. https://doi.org/10.1007/s00198-005-1957-6
Reginster, Jean Yves ; Felsenberg, Dieter ; Cooper, Cyrus ; Stakkestad, Jacob A. ; Miller, Paul D. ; Kendler, David L. ; Adami, Silvano ; McClung, Michael R. ; Bolognese, Michael A. ; Civitelli, Roberto ; Dumont, Etienne ; Bonvoisin, Bernard ; Recker, Robert R. ; Delmas, Pierre D. / A new concept for bisphosphonate therapy : A rationale for the development of monthly oral dosing of ibandronate. In: Osteoporosis International. 2006 ; Vol. 17, No. 2. pp. 159-166.
@article{e281358b80ef4e6490360800636f8683,
title = "A new concept for bisphosphonate therapy: A rationale for the development of monthly oral dosing of ibandronate",
abstract = "Oral daily and weekly bisphosphonates represent the current mainstay of treatment for postmenopausal osteoporosis (PMO). However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long term. This has prompted the development of convenient oral bisphosphonate regimens that feature simple, less frequent dosing schedules. Such regimens require high potency agents, which can be given at low effective doses and that also have good tolerability. Ibandronate is a potent, nitrogen-containing bisphosphonate with proven efficacy when given intermittently to estrogen-depleted beagle dogs, rats and cynomolgus monkeys. Clinically, a pivotal prospective study has established that oral ibandronate has significant vertebral fracture efficacy in PMO, whether given daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months; extended between-dose interval >2 months). Both oral regimens were well tolerated, which is noteworthy as patients with a history of gastrointestinal (GI) disturbance were not specifically excluded. As a result of these findings, a large, multinational, randomized, double-blind study (Monthly Oral iBandronate In LadiEs: MOBILE) is currently exploring the non-inferiority of once-monthly oral ibandronate (100 or 150 mg) to the oral daily ibandronate (2.5 mg) regimen with proven anti-fracture efficacy, in terms of lumbar spine bone mineral density (BMD) change. As with the trials investigating the weekly administration of other bisphosphonates, vertebral fracture efficacy will be inferred if the study demonstrates the non-inferiority of once-monthly ibandronate to the proven oral daily regimen in terms of spinal BMD change. The availability of this once-monthly ibandronate regimen is expected to offer benefits in terms of convenience (by having to follow dosing recommendations once a month vs. once daily or weekly) and potentially tolerability (by reducing the potential for upper GI irritation that can result from frequent, repeated exposure). Greater convenience and tolerability may enhance the therapy adherence and, hence, improve long-term therapeutic outcomes in PMO.",
author = "Reginster, {Jean Yves} and Dieter Felsenberg and Cyrus Cooper and Stakkestad, {Jacob A.} and Miller, {Paul D.} and Kendler, {David L.} and Silvano Adami and McClung, {Michael R.} and Bolognese, {Michael A.} and Roberto Civitelli and Etienne Dumont and Bernard Bonvoisin and Recker, {Robert R.} and Delmas, {Pierre D.}",
year = "2006",
month = "2",
doi = "10.1007/s00198-005-1957-6",
language = "English",
volume = "17",
pages = "159--166",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "2",

}

TY - JOUR

T1 - A new concept for bisphosphonate therapy

T2 - A rationale for the development of monthly oral dosing of ibandronate

AU - Reginster, Jean Yves

AU - Felsenberg, Dieter

AU - Cooper, Cyrus

AU - Stakkestad, Jacob A.

AU - Miller, Paul D.

AU - Kendler, David L.

AU - Adami, Silvano

AU - McClung, Michael R.

AU - Bolognese, Michael A.

AU - Civitelli, Roberto

AU - Dumont, Etienne

AU - Bonvoisin, Bernard

AU - Recker, Robert R.

AU - Delmas, Pierre D.

PY - 2006/2

Y1 - 2006/2

N2 - Oral daily and weekly bisphosphonates represent the current mainstay of treatment for postmenopausal osteoporosis (PMO). However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long term. This has prompted the development of convenient oral bisphosphonate regimens that feature simple, less frequent dosing schedules. Such regimens require high potency agents, which can be given at low effective doses and that also have good tolerability. Ibandronate is a potent, nitrogen-containing bisphosphonate with proven efficacy when given intermittently to estrogen-depleted beagle dogs, rats and cynomolgus monkeys. Clinically, a pivotal prospective study has established that oral ibandronate has significant vertebral fracture efficacy in PMO, whether given daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months; extended between-dose interval >2 months). Both oral regimens were well tolerated, which is noteworthy as patients with a history of gastrointestinal (GI) disturbance were not specifically excluded. As a result of these findings, a large, multinational, randomized, double-blind study (Monthly Oral iBandronate In LadiEs: MOBILE) is currently exploring the non-inferiority of once-monthly oral ibandronate (100 or 150 mg) to the oral daily ibandronate (2.5 mg) regimen with proven anti-fracture efficacy, in terms of lumbar spine bone mineral density (BMD) change. As with the trials investigating the weekly administration of other bisphosphonates, vertebral fracture efficacy will be inferred if the study demonstrates the non-inferiority of once-monthly ibandronate to the proven oral daily regimen in terms of spinal BMD change. The availability of this once-monthly ibandronate regimen is expected to offer benefits in terms of convenience (by having to follow dosing recommendations once a month vs. once daily or weekly) and potentially tolerability (by reducing the potential for upper GI irritation that can result from frequent, repeated exposure). Greater convenience and tolerability may enhance the therapy adherence and, hence, improve long-term therapeutic outcomes in PMO.

AB - Oral daily and weekly bisphosphonates represent the current mainstay of treatment for postmenopausal osteoporosis (PMO). However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long term. This has prompted the development of convenient oral bisphosphonate regimens that feature simple, less frequent dosing schedules. Such regimens require high potency agents, which can be given at low effective doses and that also have good tolerability. Ibandronate is a potent, nitrogen-containing bisphosphonate with proven efficacy when given intermittently to estrogen-depleted beagle dogs, rats and cynomolgus monkeys. Clinically, a pivotal prospective study has established that oral ibandronate has significant vertebral fracture efficacy in PMO, whether given daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months; extended between-dose interval >2 months). Both oral regimens were well tolerated, which is noteworthy as patients with a history of gastrointestinal (GI) disturbance were not specifically excluded. As a result of these findings, a large, multinational, randomized, double-blind study (Monthly Oral iBandronate In LadiEs: MOBILE) is currently exploring the non-inferiority of once-monthly oral ibandronate (100 or 150 mg) to the oral daily ibandronate (2.5 mg) regimen with proven anti-fracture efficacy, in terms of lumbar spine bone mineral density (BMD) change. As with the trials investigating the weekly administration of other bisphosphonates, vertebral fracture efficacy will be inferred if the study demonstrates the non-inferiority of once-monthly ibandronate to the proven oral daily regimen in terms of spinal BMD change. The availability of this once-monthly ibandronate regimen is expected to offer benefits in terms of convenience (by having to follow dosing recommendations once a month vs. once daily or weekly) and potentially tolerability (by reducing the potential for upper GI irritation that can result from frequent, repeated exposure). Greater convenience and tolerability may enhance the therapy adherence and, hence, improve long-term therapeutic outcomes in PMO.

UR - http://www.scopus.com/inward/record.url?scp=30144440302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30144440302&partnerID=8YFLogxK

U2 - 10.1007/s00198-005-1957-6

DO - 10.1007/s00198-005-1957-6

M3 - Review article

VL - 17

SP - 159

EP - 166

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 2

ER -